Latest news with #MatthieuMasselin
Yahoo
12-06-2025
- Business
- Yahoo
Wandercraft raises $75m in funding to introduce self-balancing exoskeleton
Robotics company Wandercraft has raised $75m in a Series D funding round to introduce the self-balancing personal exoskeleton, Eve, to market by 2026. This investment will fuel the company's growth and the expansion of its flagship rehabilitation system, Atalante X, which received FDA clearance. After receiving second clearance, Atalante X's use was expanded to US hospitals and clinics. It will also support the development and deployment of Calvin-40, Wandercraft's humanoid robot. The Series D round saw significant contributions from Renault Group, PSIM fund, Quadrant Management, and Teampact Ventures, among others. Since its last funding round, Wandercraft has experienced substantial growth, with a tenfold revenue increase propelled by the commercial expansion in the US. The Series D funding follows a strategic partnership and minority stake acquisition by Renault Group, which will leverage its industrial know-how to scale up production of exoskeletons and robots of Wandercraft. This industrial-grade robot, capable of performing physically demanding tasks, is said to have been developed in just 40 days using Wandercraft's quick development process and integrated with NVIDIA's Isaac technologies. Wandercraft co-founder and CEO Matthieu Masselin said: "The momentum we've achieved over the past few years is extraordinary. 'We've expanded globally, launched pivotal clinical trials, readied the commercialisation of Eve, our personal exoskeleton, and entered a landmark partnership with Renault Group.' Wandercraft's Atalante X is currently leveraged to assist individuals with disabilities in over 100 rehabilitation centres across four continents. The introduction of Eve aims to aid the users of wheelchairs by enabling standing and walking in daily life. "Wandercraft raises $75m in funding to introduce self-balancing exoskeleton" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
12-06-2025
- Business
- Yahoo
Wandercraft raises $75m in funding to introduce self-balancing exoskeleton
Robotics company Wandercraft has raised $75m in a Series D funding round to introduce the self-balancing personal exoskeleton, Eve, to market by 2026. This investment will fuel the company's growth and the expansion of its flagship rehabilitation system, Atalante X, which received FDA clearance. After receiving second clearance, Atalante X's use was expanded to US hospitals and clinics. It will also support the development and deployment of Calvin-40, Wandercraft's humanoid robot. The Series D round saw significant contributions from Renault Group, PSIM fund, Quadrant Management, and Teampact Ventures, among others. Since its last funding round, Wandercraft has experienced substantial growth, with a tenfold revenue increase propelled by the commercial expansion in the US. The Series D funding follows a strategic partnership and minority stake acquisition by Renault Group, which will leverage its industrial know-how to scale up production of exoskeletons and robots of Wandercraft. This industrial-grade robot, capable of performing physically demanding tasks, is said to have been developed in just 40 days using Wandercraft's quick development process and integrated with NVIDIA's Isaac technologies. Wandercraft co-founder and CEO Matthieu Masselin said: "The momentum we've achieved over the past few years is extraordinary. 'We've expanded globally, launched pivotal clinical trials, readied the commercialisation of Eve, our personal exoskeleton, and entered a landmark partnership with Renault Group.' Wandercraft's Atalante X is currently leveraged to assist individuals with disabilities in over 100 rehabilitation centres across four continents. The introduction of Eve aims to aid the users of wheelchairs by enabling standing and walking in daily life. "Wandercraft raises $75m in funding to introduce self-balancing exoskeleton" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
06-06-2025
- Automotive
- Forbes
Renault Is Now A Strategic Partner And Investor In Wandercraft
Sneak peek of the Calvin-40 The Renault Group has finalized a minority investment in the French self-balancing exoskeleton developer Wandercraft. This agreement unlocks new funding and serves as a vote of confidence in the technology that enables people confined to a wheelchair to stand and walk again without the need for crutches or walkers. Furthermore, the Renault Group will leverage Wandercraft's technical expertise to develop a new line of humanoid robots. This strategic partnership is initially focusing on Calvin, a line of next-generation robots for manufacturing operations (a sneak peek of the Calvin-40 is featured above). The intent is for these robots to perform tasks that require handling of loads in body positions that put too much wear and tear on workers' bodies. Finally, the partnership envisions leveraging Renault's assembly expertise to make robots and exoskeletons more affordable and easier to produce at scale. 'We are proud to continue advancing our mission through this strategic partnership. After millions of steps, and numerous awards recognizing our use of AI for good, this move takes us to the next level. As a world-class manufacturer, Renault Group strengthens our ability to produce at scale while increasing access, which remains critical for our soon-to-be customers walking again in Eve. Renault Group also brings tremendous technological synergies and represents our very first customer in a growing list of clients.' - Matthieu Masselin, CEO and co-founder of Wandercraft. 'This partnership with Wandercraft is a forward-looking move. It will allow us to accelerate on automation and to develop robots for our specific auto industrial use, giving us the opportunity to concentrate our people on more value-adding tasks and alleviate operators from painful and non-ergonomics duties. It will drive productivity through the acceleration of production time and cost reduction. In the end, it makes a lot of sense to combine Wandercraft's unique expertise and technology in exoskeletons and robots, with Renault Group's strong industrial capacity and design-to-cost know-how to bring the production of robots at scale' said Thierry Charvet, Chief Industry and Quality Officer of Renault Group. Indeed, Renault Group's trust in Wandercraft appears to be well placed. Wandercraft's self-balancing exoskeleton won the Artificial Intelligence Innovation Award at SXSW 2025. Wandercraft's use of AI was also highlighted in NVIDIA's CEO Keynote speech at CES 2025, Las Vegas. The company was able to compete by placing a mannequin inside their exoskeleton and still won first place in two disciplines at Humanoids 24. Finally, this isn't even the first time an exoskeleton developer has applied their expertise to the world of humanoid robotics. That honor goes to Fourier, which launched the GR-1 humanoid robot five years after releasing their first walking-assist exoskeleton. The Renault Group has chosen not only to invest in Wandercraft but also to partner with them in creating new and more affordable robotic solutions that improve people's lives.
Yahoo
22-05-2025
- Health
- Yahoo
Wandercraft Celebrates Opening of 'Walk in New York' to Restore Upright Mobility for People with Mobility Disabilities
Wandercraft's Walk in New York NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Wandercraft, a global leader in robotic mobility solutions as the AI-powered Personal Exoskeleton, officially opened its doors today to Walk in New York by Wandercraft, a first-of-its-kind private practice established in partnership with local Physical Therapists. The new center marks a bold step forward in restoring upright, hands-free mobility to individuals with severe walking impairments through advanced robotics and clinical innovation. Walk in New York provides patients with access to rehabilitation in Wandercraft's flagship exoskeleton, the FDA-cleared Atalante X, through regular sessions guided by licensed Physical Therapists. The center's goal is simple yet profound: to demonstrate that movement is medicine, and that hands-free walking after mobility loss is no longer a distant dream. 'Our mission has always been to restore everyday mobility, building hand-in-hand with the community of people we serve,' said Matthieu Masselin, CEO of Wandercraft. 'Walk in New York is a space where innovation meets the real world. The team now has the powerful opportunity to work alongside our users, meet their families, hear their stories, and become an active participant in their mobility journey inside and outside of the device.' The center is welcoming patients from across the country with a wide variety of conditions that limit walking, including: Stroke Spinal cord injury Traumatic brain injury Multiple sclerosis Cerebral palsy Parkinson's disease Vestibular disorders Concussion Balance disorders In addition to Atalante X, the Walk in New York offers therapy in a host of rehabilitation innovations, such as Intensive Virtual Stimulation by Dessintey and a Virtual Reality Treadmill by ezyGain. As Wandercraft moves forward with its vision of bringing the Personal Exoskeleton to market, this center will eventually serve as the hub where individuals can receive their devices, undergo training, and access ongoing support. This marks a significant step toward Wandercraft's mission of making everyday mobility accessible to everyone through advanced robotics technology. The opening celebration features remarks from leaders in both the public and private sectors who are committed to health equity and accessibility. This includes Commissioner Christina Curry from the Mayor's Office for People with Disabilities, Cecilia Kushner, Chief Strategy Officer at the NYC Economic Development Corporation (NYCEDC), and Seema Kumar, CEO of Cure, a healthcare innovation hub. 'Walk in New York is a powerful example of what happens when technology meets community,' said Commissioner Christina Curry. 'By placing this center in the heart of New York City, Wandercraft is showing that accessibility isn't an afterthought, it's foundational. This is about applying truly innovative technology to tackle systemic barriers and expand opportunities for people with mobility disabilities to live with dignity.' "Congratulations to Wandercraft on the opening of the Walk in New York by Wandercraft rehab center. Wandercraft's groundbreaking innovation will continue to help people with mobility impairments have fuller, freer lives,' said NYCEDC President and CEO Andrew Kimball. 'As home to one of the fastest growing life sciences ecosystems and the applied AI capital of the world, New York City is the premier place to do business. We are thrilled that Wandercraft chose New York City for its U.S. Headquarters and its continued growth.' 'Wandercraft's breakthrough work reflects the kind of transformative innovation Cure was built to nurture,' said Cure's Seema Kumar. 'We are proud to support this vital endeavor. Walk in New York is about more than clinical care – it's about building real connection and fostering community between our ecosystem and the patients they serve. It exemplifies Cure's mission to advance health by empowering entrepreneurs to turn bold ideas into real-world impact.' Wandercraft opened its US headquarters at Cure in 2023. In recognition of the center's contributions to accessibility, equity, and innovation in healthcare, New York City Mayor Eric L. Adams sent an official Certificate of Recognition that honors Wandercraft's role in expanding access to next-generation robotics, virtual reality, and visual simulation therapies for individuals living with neurological conditions such as spinal cord injury, multiple sclerosis, and stroke. He said: 'I applaud this groundbreaking enterprise for its efforts to forge a brighter, healthier, more mobile future for all.' To learn more about Walk in New York, or to book a session, visit: If you or someone you know is interested in participating in the clinical trial for the Personal Exoskeleton, please email: clinicaltrials@ About Wandercraft Wandercraft is on a mission to give everyone the opportunity to stand up and walk again. Known for the first-of-its-kind Personal Exoskeleton, Wandercraft is building the next generation of solutions to restore walking ability at home and in rehabilitation, including the Atalante X – a revolutionary tool in use within inpatient and outpatient rehab centers worldwide. By blending advanced robotics with a deeply human purpose, Wandercraft aims to provide new options for movement and soon transform the way wheelchair users experience walking mobility in their everyday lives. Committed to innovation and accessibility, Wandercraft welcomes collaboration with rehabilitation centers, healthcare professionals, and the broader community of wheelchair users to expand opportunities in modern mobility. For more information, visit Media Contact Lilly Kofler Global Head of Marketing & Communications A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
